Apricus Bio APRI
Apricus Bio APRI NexACT
Apricus Bio APRI NexACT
HOME ABOUT APRICUS PRODUCTS DEVELOPMENT PIPELINE INVESTOR RELATIONS ANALYST COVERAGE

Recent News

May10

Apricus Biosciences Provides First Quarter 2013 Corporate Update

May07

Apricus Biosciences Announces First Quarter 2013 Financial Results Conference Call

May07

Apricus Biosciences Announces Poster Presentation of Vitaros® Data in Men Previously Unresponsive to PDE-5 Inhibitors at American Urological Association Annual Meeting

See more news
Recent Events

Apricus Biosciences Corporate Presentation Annual Shareholders Meeting May 15, 2013

Listen to Q1 2013 Earnings Conference Call
 


About Apricus Bio

Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets innovative treatments that help large patient populations across numerous, high-demand therapeutic classes. The Company has a strong pipeline of multiple late-stage product opportunities, primarily in the area of sexual health.

Femprox® (alprostadil 0.4% topical cream) is a product candidate for the treatment of female sexual arousal disorder (FSAD). Femprox® is a topical, on-demand route of administration and targets an indication in which no product has been approved in the U.S. to date to treat FSAD, a persistent or recurring inability to attain or maintain adequate sexual arousal.

Our vision is to be a leader in the development and commercialization of innovative products that improve sexual health.

Apricus Bio's growth strategy is to acquire, develop, and commercialize new products through strategic partnerships. The Company currently has commercial partnerships with multiple large pharmaceutical companies including Abbott Laboratories, Sandoz, Warner Chilcott and Bracco.

Apricus Biosciences is headquartered in San Diego, CA and is publicly traded on the Nasdaq Capital Market under the ticker symbol APRI.


Careers      Contact Us      Terms of Use Agreement      Privacy Policy      Safe Harbor       Subscribe      Sitemap

Apricus Bio APRI